Cellectis to Transform Into In Vivo Gene Editing Company

04:55 AM EDT, 09/14/2026 (MT Newswires) -- Cellectis (ALCLS.PA) said Monday it plans to focus on becoming an in vivo gene editing company after a strategic review. The move, approved by the board on Sept. 11, is expected to extend the company's cash runway into the second half of 2028 and support the development of Cellectis' in vivo gene editing pipeline, including its Heal-101 and Heal-201 programs.